secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001708599-25-000122
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics draws first $5M tranche from $20M note for SER-252 Parkinson's trial
--------------------------------------------------------------------------------

- Received $5 million initial tranche under up to $20 million convertible note financing agreement.
- Proceeds to fund registrational Phase 1b trial of SER-252 for advanced Parkinson's disease.
- IND submitted to FDA and HREC approval received in Australia; global trial initiation in Q4 2025.
- Phase 1b trial design: randomized, double-blind, placebo-controlled with SAD (n=40) and MAD (n=48) cohorts.
- Subsequent tranches tied to development milestones including patient enrollment in the clinical trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000122/0001708599-25-000122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000122/ser-20251006.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer